Larimar Therapeutics, Inc. (LRMR)

NASDAQ: LRMR · Real-Time Price · USD
4.290
-0.060 (-1.38%)
At close: Oct 21, 2025, 4:00 PM EDT
4.280
-0.010 (-0.23%)
After-hours: Oct 21, 2025, 7:25 PM EDT
-1.38%
Market Cap367.18M
Revenue (ttm)n/a
Net Income (ttm)-99.79M
Shares Out 85.59M
EPS (ttm)-1.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,880,876
Open4.400
Previous Close4.350
Day's Range4.180 - 4.460
52-Week Range1.610 - 9.500
Beta1.00
AnalystsStrong Buy
Price Target16.71 (+289.51%)
Earnings DateNov 14, 2025

About LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Carole Ben-Maimon
Employees 65
Stock Exchange NASDAQ
Ticker Symbol LRMR
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for LRMR stock is "Strong Buy." The 12-month stock price target is $16.71, which is an increase of 289.51% from the latest price.

Price Target
$16.71
(289.51% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

LOS ANGELES , Oct. 16, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or "the Company") (NASDAQ: LRMR)...

5 days ago - PRNewsWire

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , Oct. 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Larimar Therapeutics...

5 days ago - PRNewsWire

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR

LOS ANGELES--(BUSINESS WIRE)--Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR.

6 days ago - Business Wire

Larimar Therapeutics, Inc. - Special Call

Larimar Therapeutics, Inc. - Special Call Company Participants Carole Ben-Maimon - CEO, President & Director Conference Call Participants Alexandra Folias Yatin Suneja - Guggenheim Securities, LLC, Re...

22 days ago - Seeking Alpha

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injec...

22 days ago - Benzinga

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia

BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...

22 days ago - GlobeNewsWire

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT

23 days ago - GlobeNewsWire

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

* Pro forma cash, cash equivalents, and marketable securities of $203.6 million reflects $138.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 combined with the $65.1 ...

2 months ago - GlobeNewsWire

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...

2 months ago - GlobeNewsWire

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...

2 months ago - GlobeNewsWire

Larimar Therapeutics Announces Proposed Underwritten Public Offering

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...

3 months ago - GlobeNewsWire

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

BALA CYNWYD, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...

3 months ago - GlobeNewsWire

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA Written FDA recommendations for safety database include a total of at least ...

4 months ago - GlobeNewsWire

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...

4 months ago - GlobeNewsWire

Larimar Therapeutics Reports First Quarter 2025 Financial Results

FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking ac...

6 months ago - GlobeNewsWire

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

BALA CYNWYD, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...

7 months ago - GlobeNewsWire

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...

8 months ago - GlobeNewsWire

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

BALA CYNWYD, Pa., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...

9 months ago - GlobeNewsWire

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels f...

10 months ago - Seeking Alpha

What's Going On With Larimar Therapeutics Stock On Tuesday?

On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered...

11 months ago - Benzinga

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered...

11 months ago - Benzinga

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

BALA CYNWYD, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) --  Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...

11 months ago - GlobeNewsWire

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

BALA CYNWYD, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for ...

1 year ago - GlobeNewsWire

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Oppenheimer has initiated coverage on Larimar Therapeutics LRMR, a clinical-stage biotechnology company focused on developing treatments for rare diseases.

1 year ago - Benzinga

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a sol...

1 year ago - Seeking Alpha